Novartis to set up Regional R&D Center in Budapest
Novartis, one of the world's leading pharmaceutical companies, is planning to set up a new R&D center in Budapest, which will coordinate clinical research in a dozen countries around the globe, according to a press release sent to the Budapest Business Journal.
The Swiss company, which develops, manufactures, and distributes innovative medicines, has been a major player in Hungarian clinical research for decades and one of the country's largest investors.
The decision for Hungary to take the lead in clinical research in dozens of countries around the world was based on the achievements of recent years and the committed support of the Hungarian government, represented by Minister of Foreign Affairs and Trade Péter Szijjártó at the launch event in Budapest, the company noted.
Szijjártó said around 10,000 Hungarians had participated in Novartis trials in the past 10 years.
"Innovation is key to building sustainable healthcare systems in Europe. With this in mind, it is a particularly exciting opportunity for us to place greater emphasis on clinical trials in Hungary as part of our efforts to improve patient access to advanced therapies. This investment has been made possible by the Hungarian government's ambition to make the country a leader in innovation in Europe. We look forward to continuing our partnership with Hungary and working with the country's top researchers," said Haseeb Ahmad, president of Novartis Europe, at the press conference.
The company is involved in around 100 clinical research programs each year, involving more than 1,000 domestic patients each year.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.